{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:48:16Z","timestamp":1794937696807,"version":"4.9.1"},"reference-count":74,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,19]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes\/neoplasms (HR-MDS) remains monotherapy with a hypomethylating agent (HMA), including azacitidine, decitabine, or oral decitabine\/cedazuridine. Many attempts using HMA-based combinations have failed to improve upon HMA monotherapy. Although promising efficacy was observed in early-phase clinical trials with several agents, subsequent randomized phase 3 trials failed to confirm improvements in complete response rates or overall survival. In this review, we discuss lessons learned from the recently reported negative trials of azacitidine in combination with eprenetapopt (APR-246), magrolimab, pevonedistat, sabatolimab, tamibarotene, and venetoclax. First, we make a case for emphasizing biological classification rather than disease risk status alone to select patients for HR-MDS trials. Second, we argue that patients with TP53-inactivated MDS and chronic myelomonocytic leukemia should be treated in dedicated clinical trials. Alternatively, if TP53-inactivated MDS is included in HR-MDS trials, then randomization stratification by TP53 inactivation status should be considered. Third, we caution against ignoring signals of excessive toxicity and premature discontinuation of investigational agent observed in early-phase trials. Fourth, we show that the International Working Group (IWG) 2006 response criteria, long used in HR-MDS trials, can both overestimate and underestimate the true therapeutic benefit. Instead, we advocate for using the IWG 2023 response criteria to better capture clinically meaningful benefits in HR-MDS. Lastly, we emphasize the need for the scientific community to access patient-level data and samples from failed phase 3 trials in an efficient and expedited fashion to inform the development of subsequent trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029727","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:23:35Z","timestamp":1762017815000},"page":"811-820","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials"],"prefix":"10.1182","volume":"147","author":[{"given":"Maximilian","family":"Stahl","sequence":"first","affiliation":[{"name":"Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2026021911210724500_bib1","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026021911210724500_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026021911210724500_bib3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"issue":"30","key":"2026021911210724500_bib4","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026021911210724500_bib5","doi-asserted-by":"crossref","first-page":"460.e1","DOI":"10.1016\/j.jtct.2023.04.011","article-title":"Transplantation referral patterns for patients with newly diagnosed higher-risk myelodysplastic syndromes and acute myeloid leukemia at academic and community sites in the Connect\u00ae myeloid disease registry: potential barriers to care","volume":"29","author":"Tomlinson","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2026021911210724500_bib6","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.bbmt.2017.03.020","article-title":"Allogeneic hematopoietic stem cell transplantation is underutilized in older patients with myelodysplastic syndromes","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2026021911210724500_bib8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2015.283","article-title":"Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides","volume":"30","author":"Zeidan","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2026021911210724500_bib9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2026021911210724500_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-018-0081-8","article-title":"Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?","volume":"8","author":"Zeidan","year":"2018","journal-title":"Blood Cancer J"},{"issue":"17","key":"2026021911210724500_bib11","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026021911210724500_bib12","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1002\/cncr.25774","article-title":"Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes","volume":"117","author":"Silverman","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"2026021911210724500_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clml.2022.11.002","article-title":"Azacitidine monotherapy in patients with treatment-na\u00efve higher-risk myelodysplastic syndrome: a systematic literature review and meta-analysis","volume":"23","author":"Hasegawa","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"2026021911210724500_bib14","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026021911210724500_bib15","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","article-title":"Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation","volume":"131","author":"Zeidan","year":"2018","journal-title":"Blood"},{"issue":"14","key":"2026021911210724500_bib16","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026021911210724500_bib17","unstructured":"APR-246 & azacitidine for the treatment of TP53 mutant myelodysplastic syndromes (MDS). ClinicalTrials.gov identifier: NCT03745716. Updated 18 March 2025. Accessed 6 November 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03745716."},{"issue":"15","key":"2026021911210724500_bib18","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026021911210724500_bib19","unstructured":"Gilead\n          . ENHANCE Data Summary. Accessed 6 November 2025. https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/other\/magrolimab-trials-summary.pdf."},{"issue":"17","key":"2026021911210724500_bib20","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ad\u00e8s","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026021911210724500_bib21","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026021911210724500_bib22","unstructured":"ClinicalTrials Arena\n          . Novartis Discontinues Blood Cancer Candidate After Phase III Flunk. Accessed 6 November 2025. https:\/\/www.clinicaltrialsarena.com\/news\/sabotolimab-blood-cancer-pivotal-flop\/."},{"issue":"16","key":"2026021911210724500_bib23","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1182\/bloodadvances.2025016229","article-title":"Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS","volume":"9","author":"DeZern","year":"2025","journal-title":"Blood Adv"},{"issue":"11","key":"2026021911210724500_bib24","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.2024025464","article-title":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes","volume":"145","author":"Garcia","year":"2025","journal-title":"Blood"},{"key":"2026021911210724500_bib25","unstructured":"AbbVie\n          . AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes. Accessed 6 November 2025. https:\/\/news.abbvie.com\/2025-06-16-AbbVie-Provides-Update-on-VERONA-Trial-for-Newly-Diagnosed-Higher-Risk-Myelodysplastic-Syndromes."},{"issue":"suppl 1","key":"2026021911210724500_bib26","doi-asserted-by":"crossref","first-page":"S644","DOI":"10.1016\/S2152-2650(25)02083-X","article-title":"Primary analysis of the randomized, phase 3 VERONA study of venetoclax with azacitidine versus placebo with azacitidine in patients with treatment-na\u00efve, intermediate and higher-risk myelodysplastic syndromes [abstract]","volume":"25","author":"Garcia-Manero","year":"2025","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"11","key":"2026021911210724500_bib27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2026021911210724500_bib28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nm.4165","article-title":"Therapeutic targeting of splicing in cancer","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"issue":"12","key":"2026021911210724500_bib29","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2026021911210724500_bib30","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41375-023-02050-4","article-title":"E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial","volume":"37","author":"Bewersdorf","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"2026021911210724500_bib31","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2026021911210724500_bib64","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.22.00437","article-title":"Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network","volume":"41","author":"Itzykson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026021911210724500_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"14","key":"2026021911210724500_bib32","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"2026021911210724500_bib33","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"15","key":"2026021911210724500_bib34","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026021911210724500_bib35","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026021911210724500_bib36","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood.2020005488","article-title":"Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes","volume":"136","author":"Nagata","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2026021911210724500_bib37","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"2026021911210724500_bib38","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-023-01855-7","article-title":"MDS subclassification\u2014do we still have to count blasts?","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"key":"2026021911210724500_bib39","doi-asserted-by":"crossref","first-page":"107736","DOI":"10.1016\/j.leukres.2025.107736","article-title":"Molecular taxonomy of MDS\/CMML patients influences responses to hypomethylating agents and clinical outcomes","volume":"156","author":"Molina","year":"2025","journal-title":"Leuk Res"},{"issue":"8","key":"2026021911210724500_bib40","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","article-title":"Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy","volume":"90","author":"Estey","year":"1997","journal-title":"Blood"},{"issue":"7","key":"2026021911210724500_bib41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"2026021911210724500_bib42","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(23)00090-X","article-title":"CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study","volume":"10","author":"Peterlin","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026021911210724500_bib43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2026021911210724500_bib45","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome","volume":"8","author":"DiNardo","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026021911210724500_bib46","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2026021911210724500_bib47","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2026021911210724500_bib53","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-024-02230-w","article-title":"Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"issue":"7","key":"2026021911210724500_bib48","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2026021911210724500_bib49","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: how can we improve outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2026021911210724500_bib50","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"28","key":"2026021911210724500_bib51","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study","volume":"41","author":"Versluis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026021911210724500_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2026021911210724500_bib54","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"13","key":"2026021911210724500_bib55","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2022009100","article-title":"Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2026021911210724500_bib56","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","article-title":"Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2026021911210724500_bib57","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1200\/JCO-24-02394","article-title":"Characterization and clinical implications of p53 dysfunction in patients with myelodysplastic syndromes","volume":"43","author":"Zampini","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026021911210724500_bib58","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-025-01276-y","article-title":"Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes","volume":"15","author":"Bao","year":"2025","journal-title":"Blood Cancer J"},{"issue":"15","key":"2026021911210724500_bib59","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026021911210724500_bib60","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"13","key":"2026021911210724500_bib61","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/bloodadvances.2024015238","article-title":"Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations","volume":"9","author":"Shah","year":"2025","journal-title":"Blood Adv"},{"issue":"13","key":"2026021911210724500_bib62","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1182\/bloodadvances.2025016336","article-title":"Can we harmonize classification of TP53 mutant MDS\/AML?","volume":"9","author":"Sallman","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026021911210724500_bib65","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"issue":"15","key":"2026021911210724500_bib66","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026021911210724500_bib67","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cam4.3608","article-title":"Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium","volume":"10","author":"Komrokji","year":"2021","journal-title":"Cancer Med"},{"issue":"suppl 1","key":"2026021911210724500_bib68","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1182\/blood-2024-208073","article-title":"Validation of recent response criteria (ELN-22, IWG-23 and PB-CR) in 1634 MDS\/CMML\/AML patients treated with HMA or HMA-Ven using CPH models and a CPH deep neural network - can or should response criteria be harmonized for similarly treated patients? [abstract]","volume":"144","author":"Pleyer","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026021911210724500_bib69","doi-asserted-by":"crossref","first-page":"100008","DOI":"10.1016\/j.bneo.2024.100008","article-title":"Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML","volume":"1","author":"Urrutia","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"suppl 1","key":"2026021911210724500_bib70","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2023-180299","article-title":"Validation of the composite complete response (cCR) definitions in the International Working Group (IWG) 2023 criteria in patients (Pts) with higher-risk myelodysplastic syndromes\/neoplasms (HR-MDS) treated with hypomethylating agents (HMA) - a large, multicenter, retrospective analysis from the validate database [abstract]","volume":"142","author":"Bewersdorf","year":"2023","journal-title":"Blood"},{"key":"2026021911210724500_bib71","unstructured":"U.S. Food and Drug Administration\n          . Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment. Accessed 6 November 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/myelodysplastic-syndromes-developing-drug-and-biological-products-treatment."},{"issue":"17","key":"2026021911210724500_bib72","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1158\/1078-0432.CCR-25-1005","article-title":"FDA approval summary: ivosidenib for treatment of adult patients with relapsed\/refractory myelodysplastic syndrome with an IDH1 mutation","volume":"31","author":"Woods","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026021911210724500_bib73","unstructured":"U.S. Food and Drug Administration\n          . Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment. Accessed 6 November 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/acute-myeloid-leukemia-developing-drugs-and-biological-products-treatment-0."},{"issue":"2","key":"2026021911210724500_bib74","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood.2023023313","article-title":"Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia","volume":"144","author":"Le","year":"2024","journal-title":"Blood"},{"key":"2026021911210724500_bib75","unstructured":"Aprea Therapeutics\n          . Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS). Accessed 6 November 2025. https:\/\/ir.aprea.com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3."},{"issue":"1","key":"2026021911210724500_bib76","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41467-018-08166-x","article-title":"A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies","volume":"10","author":"Song","year":"2019","journal-title":"Nat Commun"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025029727\/2504824\/blood_bld-2025-029727-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025029727\/2504824\/blood_bld-2025-029727-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:21:21Z","timestamp":1771518081000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/8\/811\/548015\/The-conundrum-of-drug-development-in-higher-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,2,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029727","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,19]]},"published":{"date-parts":[[2026,2,19]]}}}